Schering-Plough/Merck File Claritin, Singulair Combination
This article was originally published in The Pink Sheet Daily
NDA has been accepted by FDA for a standard 10-month review.
You may also be interested in...
Sales of Vytorin and Zetia climb 48 percent to $1.2 billion during the first quarter.
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.